# Buprenorphine, Hepatitis C Virus and Their Relationship in Rural US Populations

> **NIH NIH F30** · OHIO STATE UNIVERSITY · 2021 · $39,877

## Abstract

PROJECT SUMMARY
 Rural areas in the United States (US) are facing an epidemic of opioid use disorder (OUD) and hepatitis
C virus (HCV) infections. HCV is a costly infection with high morbidity and mortality and is primarily spread
through injection drugs use in the US. Injection drug use is of epidemic proportions as people with OUD
transition from misusing oral opioid medications to injectable forms of opioids. HCV among people who inject
drugs (PWID) may be preventable through prescribed medication-assisted treatments for OUD, such as
buprenorphine. However, this relationship is unclear in rural populations where OUD and HCV rates are high,
but access to buprenorphine is low. Our preliminary studies also indicate marked stigma and non-evidence
based prescribing habits associated with buprenorphine in rural areas. Rural community leaders have asked
for this investigation. This investigation can inform practices and policies on rural populations that are
disproportionately affected by the current opioid crisis.
 The specific aims of this research are 1) to describe differences in buprenorphine prescribing
between urban and rural US population, 2012-2017 2) to assess the relationship between access to
prescribed buprenorphine and HCV in rural Ohio, 2014-2017 and 3) to assess the relationship between
perceived access to and use of prescribed buprenorphine with HCV status among people who use
drugs (PWUD) in a rural US population in 2019. Aim 1 is informed by preliminary qualitative data from in-
depth interviews with community stakeholders and will serve as a big data health care claims investigation of
how buprenorphine may be prescribed less commonly and for shorter periods in rural areas. Aim 2 is an
ecological spatial analysis of the relationship between buprenorphine prescribers and incident HCV in rural
areas. Aim 3 is a primary respondent-driven sampling survey of PWID in rural Ohio. Aim 3 is a unique PWID-
perspective of the relationship between access and use of prescribed buprenorphine and HCV infection
incidence in rural populations.
 Each of these aims is coupled with longitudinal shadowing in infectious disease clinics locally (Ohio
State) and in rural Ohio (Southern Ohio Medical Center). Additionally, we have developed a training plan that
will provide unique skills otherwise not available in the current epidemiology doctoral or medical training
program. I plan to have a career as an independently funded physician-scientist in infectious disease
epidemiology and clinical medicine. I also plan to focus my research and clinical efforts on rural populations
like those in Southern Ohio, near where I grew up, that are disproportionately impacted by injection drug use.
Community-driven evidence-based interventions, in conjunction with dedicated health care and public health
practitioners, are needed to end the current opioid crisis.

## Key facts

- **NIH application ID:** 10138504
- **Project number:** 5F30DA050423-02
- **Recipient organization:** OHIO STATE UNIVERSITY
- **Principal Investigator:** Daniel Brook
- **Activity code:** F30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $39,877
- **Award type:** 5
- **Project period:** 2020-04-01 → 2024-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10138504

## Citation

> US National Institutes of Health, RePORTER application 10138504, Buprenorphine, Hepatitis C Virus and Their Relationship in Rural US Populations (5F30DA050423-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10138504. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*